SBI Securities’s Marker Therapeutics MRKR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$216 Sell
202
-1
-0.5% -$1 ﹤0.01% 3388
2026
Q2
$298 Hold
203
– – ﹤0.01% 3202
2026
Q1
$264 Hold
203
– – ﹤0.01% 3119
2025
Q4
$302 Hold
203
– – ﹤0.01% 3065
2025
Q3
$181 Sell
203
-1,500
-88% -$1.85K ﹤0.01% 3351
2025
Q2
$2.61K Buy
1,703
+500
+42% +$642 ﹤0.01% 2280
2025
Q1
$1.48K Buy
1,203
+1,001
+496% +$1.83K ﹤0.01% 2423
2024
Q4
$628 Buy
+202
New +$715 ﹤0.01% 2814

Other funds holding MRKR

SBI Securities's MRKR Position: Q3 2026 in Review

SBI Securities reduced its Marker Therapeutics (MRKR) stake by 0.49% in Q3 2026, selling an estimated $1 and leaving 202 shares worth $216. The position accounts for ﹤0.01% of the portfolio, ranked #3388.

SBI Securities first reported a position in MRKR in Q4 2024 and has held it in 8 quarters since. The position peaked at $2.61K in Q2 2025. 36 funds tracked by Wall St. Rank hold MRKR as of Q3 2026.

  • SBI Securities held 202 shares of Marker Therapeutics worth $216 as of Q3 2026.
  • SBI Securities sold 1 Marker Therapeutics share in Q3 2026, an estimated $1.
  • Marker Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q3 2026, its #3388 holding.
  • SBI Securities first reported a position in Marker Therapeutics in Q4 2024 and has held it in 8 quarters since.
  • SBI Securities's Marker Therapeutics position peaked at $2.61K in Q2 2025.
  • 36 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2026.

Based on SBI Securities's 13F filing for Q3 2026, filed 22 Oct 2026.